Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States

Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States

Anshul Shah,1 Jonathan C Tosh,2 Apoorva Ambavane,2 Andreas Nikolaou,2 Cosmina Hogea,3 Yevgeniy Samyshkin,4 Boris Gorsh,3 Eric M Maiese,5 Feng Wang3 1Modelling and Simulation, Evidera, Waltham, MA, USA; 2Modelling and Simulation, Evidera, London, UK; 3Value Evidence and Outcomes, GlaxoSmithKline, Upp...

Full description

Bibliographic Details
Main Authors: Shah A, Tosh JC, Ambavane A, Nikolaou A, Hogea C, Samyshkin Y, Gorsh B, Maiese EM, Wang F
Format: Article
Language:English
Published: Dove Medical Press 2021-09-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
bcma
belamaf
budget impact analysis
relapsed/refractory
multiple myeloma
payer
Online Access:https://www.dovepress.com/budget-impact-of-belantamab-mafodotin-belamaf-adoption-in-the-treatmen-peer-reviewed-fulltext-article-CEOR

Internet

https://www.dovepress.com/budget-impact-of-belantamab-mafodotin-belamaf-adoption-in-the-treatmen-peer-reviewed-fulltext-article-CEOR

Similar Items